CervoMed Reports Initial 12-Week NfL Decline in Phase 2a Trial
CervoMed reported an average reduction in plasma neurofilament light during the first 12 weeks of its Phase 2a nfvPPA trial of neflamapimod. Data at 24 weeks are due in November.
CervoMed reported an average reduction in plasma neurofilament light during the first 12 weeks of its Phase 2a nfvPPA trial of neflamapimod. Data at 24 weeks are due in November.